PRTA News and Press, Prothena Corporation plc

2026-02-27 16:24:45 ET More on Prothena Prothena Corporation plc 2025 Q4 - Results - Earnings Call Presentation Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript Prothena Corporation plc (PRTA) Presents at Evercore 8th Annual Healthcare Conference Tran...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which the Company may repur...

2026-02-19 21:24:58 ET Prothena Corporation plc (PRTA) Q4 2025 Earnings Call February 19, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript

2026-02-19 16:33:10 ET More on Prothena Prothena Corporation plc (PRTA) Presents at Evercore 8th Annual Healthcare Conference Transcript Seeking Alpha’s Quant Rating on Prothena Historical earnings data for Prothena Financial information for Prothena ...

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing ac...

Travere Therapeutics Inc. (TVTX) is expected to report $0.03 for Q4 2025 Teck Resources Ltd (TECK) is expected to report $0.59 for Q4 2025 Heidmar Maritime Holdings Corp. (HMR) is expected to report $0.05 for Q4 2025 Endava plc American Depositary Shares (each representing one Class A...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19...

TDP-43 CYTOPE ® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease pathways Systemically-administered TDP-43 CYTOPE rapidly and efficient...

Novo Nordisk’s Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo Nordisk as part of their up to $1.2 billion acquisition of Prothena’s ATTR amyloidosis business...

2025-11-06 16:10:29 ET More on Prothena Seeking Alpha’s Quant Rating on Prothena Historical earnings data for Prothena Financial information for Prothena Read the full article on Seeking Alpha For further details see: Prothena GAAP EPS of -...